In November, markets received the first hopeful phase-III trial data from a Covid-19 vaccine candidate. Pfizer is the name most closely attached to the vaccine…
In November, markets received the first hopeful phase-III trial data from a Covid-19 vaccine candidate. Pfizer is the name most closely attached to the vaccine…